Clinical Laserthermia Systems AB (publ) (STO:CLS.B)
Sweden flag Sweden · Delayed Price · Currency is SEK
4.285
-0.065 (-1.49%)
At close: May 25, 2026

STO:CLS.B Income Statement

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
14.2717.4918.788.276.272.25
Other Revenue
---00--
14.2717.4918.788.276.272.25
Revenue Growth (YoY)
-29.16%-6.90%127.03%31.99%179.20%68.54%
Cost of Revenue
5.466.578.365.289.065.88
Gross Profit
8.8110.9210.423-2.79-3.63
Selling, General & Admin
36.7937.3362.0466.1362.2954.2
Other Operating Expenses
0.260.19-0.06-0.36-0.09-0
Operating Expenses
39.6440.1164.6568.4864.6556.98
Operating Income
-30.84-29.19-54.23-65.48-67.44-60.61
Interest Expense
-0.04-0.09-0.43-9.76-10.97-6.41
Interest & Investment Income
2.21-6.830.37.42.91
Currency Exchange Gain (Loss)
---0.02-0.45-0-0.07
Other Non Operating Income (Expenses)
0.180.24-0-0-0.220.03
EBT Excluding Unusual Items
-28.48-29.04-47.86-75.39-71.24-64.14
Gain (Loss) on Sale of Investments
-5.7-13--5.48-0.03-
Pretax Income
-34.18-42.05-47.86-80.88-71.27-64.14
Earnings From Continuing Operations
-34.18-42.05-47.86-80.88-71.27-64.14
Minority Interest in Earnings
0.430.430.241.080.610.53
Net Income
-33.75-41.61-47.62-79.79-70.66-63.62
Net Income to Common
-33.75-41.61-47.62-79.79-70.66-63.62
Shares Outstanding (Basic)
282611300
Shares Outstanding (Diluted)
282611300
Shares Change (YoY)
92.75%134.96%227.83%705.35%45.02%30.24%
EPS (Basic)
-1.19-1.61-4.32-23.76-169.43-221.20
EPS (Diluted)
-1.19-1.61-4.32-23.76-169.43-221.20
Free Cash Flow
-34.79-35.91-63.93-68.6-82.1-66.32
Free Cash Flow Per Share
-1.23-1.39-5.81-20.42-196.85-230.61
Gross Margin
61.72%62.44%55.47%36.23%-44.51%-161.69%
Operating Margin
-216.13%-166.90%-288.72%-791.47%-1075.95%-2699.97%
Profit Margin
-236.57%-237.96%-253.54%-964.46%-1127.31%-2833.63%
Free Cash Flow Margin
-243.83%-205.33%-340.34%-829.16%-1309.76%-2954.16%
EBITDA
-28.24-26.6-53.93-65.14-67.05-59.93
EBITDA Margin
-197.97%-152.12%-287.10%---
D&A For EBITDA
2.592.580.30.340.390.68
EBIT
-30.84-29.19-54.23-65.48-67.44-60.61
EBIT Margin
-216.13%-166.90%-288.72%---
Revenue as Reported
-----2.41
Source: S&P Global Market Intelligence. Standard template. Financial Sources.